Premium
N ‐(2‐Hydroxypropyl)methacrylamide Copolymer–Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia
Author(s) -
Zhang Rui,
Yang Jiyuan,
Zhou Yan,
Shami Paul J.,
Kopeček Jindřich
Publication year - 2016
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201500193
Subject(s) - cytarabine , daunorubicin , myeloid leukemia , methacrylamide , pharmacology , drug , chemistry , in vivo , leukemia , chemotherapy , medicine , cancer research , copolymer , biology , acrylamide , microbiology and biotechnology , organic chemistry , polymer
There is a need for new treatment strategies of acute myeloid leukemia (AML). In this study, four different drugs, including cytarabine, daunorubicin, GDC‐0980, and JS‐K, were investigated in vitro for the two‐drug combinations treatment of AML. The results revealed that cytarabine and GDC‐0980 had the strongest synergism. In addition, cell cycle analysis was conducted to investigate the effect of the different combinations on cell division. For future in vivo application, N ‐(2‐hydroxypropyl)methacrylamide (HPMA) copolymer‐cytarabine and GDC‐0980 conjugates were synthesized, respectively. In vitro studies demonstrated that both conjugates had potent cytotoxicity and their combination also showed strong synergy, suggesting a potential chemotherapeutic strategy for future AML treatment.